Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Takeda Pharmaceutical Ltd ADR (TAK)

Takeda Pharmaceutical Ltd ADR (TAK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,704,576
  • Shares Outstanding, K 3,100,722
  • Annual Sales, $ 31,764 M
  • Annual Income, $ 2,048 M
  • 60-Month Beta 0.65
  • Price/Sales 1.57
  • Price/Cash Flow 4.50
  • Price/Book 1.03
Trade TAK with:

Options Overview Details

View History
  • Implied Volatility 32.80% ( -17.12%)
  • Historical Volatility 15.62%
  • IV Percentile 97%
  • IV Rank 57.41%
  • IV High 49.92% on 01/26/23
  • IV Low 9.71% on 08/05/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6,479
  • Volume Avg (30-Day) 503
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 8,816
  • Open Int (30-Day) 19,791

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.54
  • Growth Rate Est. (year over year) +184,900.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.27 +4.94%
on 01/10/23
16.30 -1.66%
on 01/20/23
+0.61 (+3.96%)
since 12/27/22
3-Month
12.99 +23.40%
on 11/03/22
16.30 -1.66%
on 01/20/23
+2.99 (+22.93%)
since 10/27/22
52-Week
12.28 +30.54%
on 10/21/22
16.30 -1.66%
on 01/20/23
+1.61 (+11.17%)
since 01/27/22

Most Recent Stories

More News
3 Stable Stocks to Buy This Week for Under $50

Despite the headline inflation cooling down, the Fed will likely continue raising interest rates to meet its inflation target. Moreover, S&P 500 earnings are estimated to have declined in the last quarter....

DKILY : 17.3900 (+0.23%)
JRONY : 44.1600 (+1.22%)
TAK : 16.03 (-0.43%)
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor

Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with HUTCHMED (China) Limited (Nasdaq/AIM: HCM, HKEX: 13) and its subsidiary HUTCHMED Limited, for the...

TAK : 16.03 (-0.43%)
Takeda Named Global Top Employer for Sixth Consecutive Year

Takeda ( TSE:4502/NYSE:TAK ) today announced that, for the sixth consecutive year, it was one of only 15 companies to achieve global Top Employer® certification for 2023. In addition to the global...

TAK : 16.03 (-0.43%)
1 Large-Cap Stock You Should Purchase This Week

Pharmaceutical company Novartis (NVS) maintained its growth momentum in the third quarter of fiscal 2022, and the company’s growth prospects look promising, supported by its clear focus on five core...

JNJ : 168.23 (-0.39%)
NBIX : 108.25 (-0.12%)
NVS : 89.49 (-0.39%)
TAK : 16.03 (-0.43%)
Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC

Takeda ( TSE:4502/NYSE:TAK ) today announced that EXKIVITY ® (mobocertinib) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with...

TAK : 16.03 (-0.43%)
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Takeda ( TSE:4502/NYSE:TAK ) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced topline results from the Phase 2 SEQUOIA clinical study of investigational fazirsiran (TAK-999/ARO-AAT) for...

TAK : 16.03 (-0.43%)
ARWR : 33.61 (+0.99%)
Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda ( TSE:4502/NYSE:TAK ) today announced that the totality of evidence from a pre-planned interim analysis of a pivotal Phase 3 study supports the efficacy and safety of TAK-755 as enzyme replacement...

TAK : 16.03 (-0.43%)
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, "Astellas"), Eisai Co., Ltd. (TSE: 4523, CEO: Haruo Naito, "Eisai"),...

TAK : 16.03 (-0.43%)
The Best Medical Stock to Buy Right Now for Under $100

Despite macroeconomic challenges, leading pharma company Bristol-Myers Squibb (BMY) has the robustness and resilience to deliver value for shareholders. Read on… As yet another indication of a sea...

ALPMY : 14.8800 (-1.85%)
BMY : 72.45 (-0.74%)
PFE : 43.79 (-1.04%)
TAK : 16.03 (-0.43%)
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics

Takeda ( TSE:4502/NYSE:TAK ) today announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated...

TAK : 16.03 (-0.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide...

See More

Key Turning Points

3rd Resistance Point 16.21
2nd Resistance Point 16.14
1st Resistance Point 16.08
Last Price 16.03
1st Support Level 15.96
2nd Support Level 15.89
3rd Support Level 15.83

See More

52-Week High 16.30
Last Price 16.03
Fibonacci 61.8% 14.76
Fibonacci 50% 14.29
Fibonacci 38.2% 13.82
52-Week Low 12.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar